- INDICATIONS: Radioactive diagnostic agent for positron emission tomography (PET) imaging of patients with suspected prostate cancer recurrence
- CLASS: Radiopharmaceutical, diagnostic agent
- HALF-LIFE: 20 minutes
- FDA APPROVAL DATE: 09/12/2012
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
Please login to view the rest of this drug profile.
Page last updated 07/31/2023